Throughout the last three months, 10 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...
As previously reported, Wolfe Research initiated coverage of Blueprint Medicines (BPMC) with an Outperform rating and $132 price target. The ...
Baltimore (WBFF) — Projected costs associated with school spending and the Blueprint for Maryland’s Future are surging. In ...
The Maryland House of Delegates approved an amended, comprehensive education plan Tuesday night that rejected cuts proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback